|Assessment Status||Rapid Review Complete|
|Indication||Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|
|Rapid review commissioned||03/03/2023|
|Rapid review completed||21/04/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.